💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib  20170927

By FDA, JPN

💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib

News Release | Ono Pharmaceutical Co., Ltd.

http://www.ono.co.jp/jpnw/PDF/n17_0927.pdf

More from tokioX :

  1. FDA ：Opdivo® as the First New Medication for Certain Patients with Previously Treated Small Cell Lung Cancer
  2. 🏹ITOCHU Announces Acquisition of Master License Rights to the CIMARRON Brand  20170927.
  3. 💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action)  20170927
  4. 👾Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Advanced Non-squamous Non-small Cell Lung Cancer which Has Been Previously Treated with Platinum-based Therapy in Taiwan News Release
  5. Two important clinical trials of Ono Pharmaceuticals, Opivo® (generic name: niborumab) demonstrate the benefits of three-year survival in patients   20170911
  6. Bristol-Myers Squibb and Daiichi Sankyo Announce Research Collaboration to Evaluate Opdivo® (nivolumab) and DS-8201 in HER2-Expressing Breast and Bladder Cancers
  7. Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan  2017.08.16